COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
London, UK 3 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder . The study expands COMPASS’s research pipeline in psilocybin therapy with COMP360, ...